![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Coherus to Delay BLA Submission for Neulasta Biosimilar
Coherus to Delay BLA Submission for Neulasta Biosimilar
December 16, 2015
Coherus BioSciences will delay its planned submission of a BLA for CHS-1701 — a knockoff of Amgen’s Neulasta for treatment of neutropenia — by about three months to conduct an additional pharmacokinetic and pharmacodynamic study.
According to the company, a new study will cost less than $4 million, and was not requested by the FDA.
CHS-1701 met its primary endpoints in a previous study, but missed bioequivalence endpoints due to a "low, anomalous" pharmacokinetic profile in one treatment group, Coherus said in October.
Upcoming Events
-
21Oct